Safety and efficacy of anti–tumor necrosis factor α therapy in ten patients with recent‐onset refractory reactive arthritis

Alain Meyer(Hôpitaux Universitaires de Strasbourg), Éric Houvenagel(Hôpital Saint-Philibert), Jacques Morel(Centre National de la Recherche Scientifique), Daniel Wendling(Centre Hospitalier Universitaire de Besançon), Emmanuelle Dernis(Centre Hospitalier du Mans), Thierry Schaeverbeke(Centre Hospitalier Universitaire de Bordeaux), Emmanuel Chatelus(Laboratoire National de Référence), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Olivier Richer(Boston Children's Hospital), Jean‐Marie Berthelot(Centre Hospitalier Universitaire de Nantes), Jacques‐Eric Gottenberg(Hôpitaux Universitaires de Strasbourg)
Arthritis & Rheumatism
January 28, 2011
10.1002/art.30272
Cited by 81

Related Papers

<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Lymphomas in Patients With Sjogren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses
|Blood|1997|346
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study
|Annals of the Rheumatic Diseases|2017|302